

ABL103, A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivo antitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment



ONCOLOGY	Non-Clinical
Product Type	Bispecific antibody / IO drug
Indication	B7-H4 positive solid cancer [Breast/Ovarian/NSCLC/Endometrial Cancer]
Target	B7-H4(VTCN1) and 4-1BB
MoA(Mechanism of Action)	<ul style="list-style-type: none"> B7-H4 expression dependent 4-1BB activation and tumor killing Blocks B7-H4 checkpoint activity <div style="display: flex; justify-content: space-around; align-items: flex-start;"> <div style="text-align: center;"> <p>Normal tissue</p> <ul style="list-style-type: none"> No 4-1BB clustering in the absence of TAA No Liver toxicity </div> <div style="text-align: center;"> <p>Tumor microenvironment</p> </div> </div>
Competitiveness	<ul style="list-style-type: none"> Providing new therapeutic option for B7-H4+PD-L1low cancer patients Synergic effects with immunotherapy No toxicity concern up to 100 mg/kg (Monkey/Pilot tox study)
Development Stage	Preclinical (GLP-tox study,on-going)
Route of Administration	IV